Feasibility of a New Silicone Hydrogel Lens
Launched by BAUSCH & LOMB INCORPORATED · May 25, 2010
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must have clear central corneas and be free of any anterior segment disorders.
- • Participants must be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand.
- • Participants must be myopic and require lens correction from -0.75 D to - 4.75D in each eye.
- Exclusion Criteria:
- • Participants who have worn gas permeable (GP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last three months.
- • Participants with any systemic disease affecting ocular health.
- • Participants using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.
- • Participants with an active ocular disease or are using any ocular medication.
- • Participants who have had any corneal surgery (eg, refractive surgery).
- • Participants who are allergic to any component in the study care products.
About Bausch & Lomb Incorporated
Bausch & Lomb Incorporated is a leading global eye health company dedicated to advancing the vision and well-being of individuals through innovative products and solutions. With a rich history spanning over 160 years, Bausch & Lomb specializes in the development, manufacturing, and marketing of a comprehensive range of eye care products, including contact lenses, lens care solutions, and pharmaceuticals for various ocular conditions. The company is committed to rigorous clinical research and trials to ensure the safety and efficacy of its offerings, striving to enhance patient outcomes and improve quality of life for those with vision-related challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Trial Officials
Gerard Carains, MCOptom, PhD
Study Director
Bausch & Lomb Incorporated
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials